Ranked GEO Datasets

Active GEO index contains 44582 ranked datasets; organism mixed: Homo sapiens (32595), Mus musculus (11987); assay type mixed: microarray (24223), bulk RNA-seq (18996), other assay type (1363). Rankings use the Patient tissue tumor-vs-normal intent with transparent suitability, metadata quality, and warning rules.

Gene snapshot Projects Saved searches CSV Markdown
50 shown of 160 matching datasets Scoring intent-aware-scoring-v19 Batch 37ac26514efb8b677e99d5c1de46b7a1d0a16b1bf8f9277f060eef4b0ed1de09 Intent Patient tissue tumor-vs-normal Organism Homo sapiens Assay bulk RNA-seq Intent defaults Active 5 active filters Page 2 of 4 · showing 51-100
Active intent defaults Tumor-normal onlyTissue or biopsy onlyHide biofluid/model systemsHuman onlyBulk RNA-seq only
Study designs tumor vs matched normal or tumor vs unmatched normal
Recommendation Recommended means a human bulk RNA-seq tissue or biopsy cohort with clear tumor-normal grouping and sufficient metadata for first-pass triage.
Search intent
Intent defaults Relax defaults

Showing one page of matching results. Use next/previous for browsing, or CSV/Markdown export for the full matching set.

51
GSE253906

Enhancer plasticity in endometrial tumorigenesis demarcates non-coding driver mutations and 3D genome alterations to stimulate oncogene expression [RNA-seq_ECa_patients]

Exploratory only Overall 45% Suitability 5% Metadata 70%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset can inform exploration but is not strong enough for primary analysis.

  • Tumor vs unmatched normal · Tissue · suitability 5%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 2 warnings require review.
GEO Homo sapiens bulk RNA-seq 6 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized. warning Tissue or cell type could not be normalized.
52
GSE288097

Active DNA demethylation is upstream of rod photoreceptor fate determination and required for retinal development [Human RNA-Seq]

Exploratory only Overall 45% Suitability 5% Metadata 70%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset can inform exploration but is not strong enough for primary analysis.

  • Tumor vs unmatched normal · Tissue · suitability 5%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 3 warnings require review.
GEO Homo sapiens bulk RNA-seq 5 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Dataset has fewer than six samples and should not be treated as a high-confidence cohort without manual review. warning Disease or condition label could not be normalized. warning Tissue or cell type could not be normalized.
53
GSE304666

Transcriptomic profiling of meningiomas reveals SMARCB1 mutation-driven immunosuppression via IL-17/CSF1 axis

Exploratory only Overall 45% Suitability 5% Metadata 70%
Case tumor sample Control control
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset can inform exploration but is not strong enough for primary analysis.

  • Tumor vs unmatched normal · Tissue · suitability 5%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 2 warnings require review.
GEO Homo sapiens bulk RNA-seq 14 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized. warning Tissue or cell type could not be normalized.
54
GSE308395

Identification of Differentially Expressed Genes and Associated Immune Cell Types In South African Gallbladder Cancer Patients

Exploratory only Overall 45% Suitability 5% Metadata 70%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset can inform exploration but is not strong enough for primary analysis.

  • Tumor vs unmatched normal · Tissue · suitability 5%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 2 warnings require review.
GEO Homo sapiens bulk RNA-seq 10 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized. warning Tissue or cell type could not be normalized.
55
GSE57401

Transcriptome analysis of human reninomas as an approach to understanding juxtaglomerular cell biology

Exploratory only Overall 45% Suitability 5% Metadata 70%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset can inform exploration but is not strong enough for primary analysis.

  • Tumor vs unmatched normal · Tissue · suitability 5%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 2 warnings require review.
GEO Homo sapiens bulk RNA-seq 8 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized. warning Tissue or cell type could not be normalized.
56
GSE62944

Alternatively processed and compiled RNA-Sequencing and clinical data for thousands of samples from The Cancer Genome Atlas

Exploratory only Overall 45% Suitability 5% Metadata 70%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset can inform exploration but is not strong enough for primary analysis.

  • Tumor vs unmatched normal · Tissue · suitability 5%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 3 warnings require review.
GEO Homo sapiens bulk RNA-seq 2 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Total sample count is below the minimum needed for two comparison groups. warning Disease or condition label could not be normalized. warning Tissue or cell type could not be normalized.
57
GSE107502

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 (RNA-Seq)

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Biopsy
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Biopsy · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 28 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

58
GSE110114

A practical evaluation of alignment algorithms for RNA variant calling analysis

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs matched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs matched normal · Tissue · suitability 0%.
  • Prioritized for patient tissue tumor-vs-normal triage.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 13 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

59
GSE118206

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage (RNA-seq)

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 36 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

60
GSE119168

N6-methyladenosine (m6A) profiling of ovarian cancer tissues

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 26 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

61
GSE119794

Network-based integration of mRNA and miRNA profiles reveals new target genes involved in pancreatic cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: gastrointestinal cancer is present but colorectal metadata is not explicit.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 40 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
62
GSE123762

The Androgen Receptor is a Tumor Suppressor in Estrogen Receptor Positive Breast Cancer [Normal and tumor patient-derived explant RNA-seq]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case breast cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 50 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

63
GSE133206

RNA-seq of human normal lung and lung cancer tissue

Not suitable Overall 34% Suitability 0% Metadata 100%
Case lung cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 2 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Total sample count is below the minimum needed for two comparison groups.
64
GSE133626

Genome wide transcriptome analysis of patient matched prostate cancer using NGS technology

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 60 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

65
GSE135298

Breast Cancer - immune clusters - RNA-seq

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 93 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

66
GSE140343

Gene expression profile of clinical LUAD tumors and their paired non-cancerous adjacent tissues by RNA-seq analysis

Not suitable Overall 34% Suitability 0% Metadata 100%
Case lung cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 100 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

67
GSE141142

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 24 samples intent-aware-scoring-v19
GEO source Trusted counts
info Ambiguous sample metadata was detected in 3 sample(s): GSM4196016 matched "unknown"; GSM4196017 matched "unknown"; GSM4196021 matched "unknown". Review these samples before inclusion or manual group assignment.
68
GSE160626

Identification of transcriptional difference between platinum-sensitive and resistant patients with ovarian cancer (OV)

Not suitable Overall 34% Suitability 0% Metadata 100%
Case ovarian cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 25 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

69
GSE168292

Androgen Deprivation Alters the Transcriptome of Endothelial Cells More Dramatically in Human Prostate Cancer Tissue than in Benign Prostate Tissue

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 2 warnings require review.
GEO Homo sapiens bulk RNA-seq 127 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Multiple sample type labels or exclusion flags were detected. warning Xenograft samples appear to be included.
70
GSE171415

Genomic and evolutionary classification of lung cancer in never smokers

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 67 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

71
GSE173991

Integrated Metabolic Profiling and Gene Expression Analysis Reveals Therapeutic Modalities in Breast Cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs matched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs matched normal · Tissue · suitability 0%.
  • Prioritized for patient tissue tumor-vs-normal triage.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 2 warnings require review.
GEO Homo sapiens bulk RNA-seq 40 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Multiple sample type labels or exclusion flags were detected. warning Xenograft samples appear to be included.
72
GSE179509

Distinctive properties of endothelial cells from tumor and normal tissue in human breast cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 4 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Dataset has fewer than six samples and should not be treated as a high-confidence cohort without manual review.
73
GSE192410

CircRNA expression profiling in human ovarian cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 6 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
74
GSE192849

CircRNA expression profiling in human breast cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs matched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs matched normal · Tissue · suitability 0%.
  • Prioritized for patient tissue tumor-vs-normal triage.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 6 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
75
GSE210787

Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic peptides [RNA-Seq]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 12 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
76
GSE210790

Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic peptides [circRNA-seq]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 12 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
77
GSE212991

Genome-wide expression profiling reveals novel biomarkers in epithelial ovarian cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 6 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

78
GSE221107

The landscape of enhancer transcription in prostate cancer [RNA-Seq]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case prostate cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 40 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

79
GSE22260

Comparative transcriptomic analysis of prostate cancer and matched normal tissue using RNA-seq

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs matched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs matched normal · Tissue · suitability 0%.
  • Prioritized for patient tissue tumor-vs-normal triage.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 30 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

80
GSE226307

The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100P Gene Expression in Cells and in an In Vivo Model of Pancreatic Cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case pancreatic cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: gastrointestinal cancer is present but colorectal metadata is not explicit.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 7 samples intent-aware-scoring-v19
GEO source Trusted counts
critical Animal sample markers were detected in a human dataset.
81
GSE228458

Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1 [human]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case breast cancer Control healthy control
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 13 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

82
GSE229509

Transcriptomic Profiling for Prognostic Biomarkers in Early-stage Squamous Cell Lung Cancer (SqCLC)

Not suitable Overall 34% Suitability 0% Metadata 100%
Case lung cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 26 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

83
GSE229571

Tumor-specific circRNAs elicit anti-tumor immune response via encoding cryptic peptides [RNA-Seq 2]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 12 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

84
GSE230087

Identification of prognostic biomarkers in early stage squamous cell lung cancer (LUSC) by transcriptomic and miRNA profiling [sRNA-Seq]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case lung cancer Control healthy control
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 18 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
85
GSE244311

Improved lung cancer classification by employing diverse molecular features of microRNAs

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 38 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

86
GSE254362

CircPOLA2 sensitizes NSCLC cells to ferroptosis and suppresses tumorigenesis via the Merlin-YAP signaling pathway

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 8 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

87
GSE254461

Machine-learning model based on glycosyltransferase expression predicts multiple cancer types, subtypes and survival probability

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: multi-cancer cohort is only secondary for colorectal ranking.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 57 samples intent-aware-scoring-v19
GEO source Trusted counts
critical Animal sample markers were detected in a human dataset.
88
GSE306117

Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control healthy control
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 74 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

89
GSE40049

Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs matched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs matched normal · Tissue · suitability 0%.
  • Prioritized for patient tissue tumor-vs-normal triage.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 38 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

90
GSE52248

Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 18 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

91
GSE53829

A Ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 59 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
92
GSE80400

Small RNA sequencing of human prostate cancer samples

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 2 warnings require review.
GEO Homo sapiens bulk RNA-seq 11 samples intent-aware-scoring-v19
GEO source Trusted counts
critical Animal sample markers were detected in a human dataset. warning Secondary RNA assay context such as small RNA, miRNA, circRNA, or non-coding RNA was detected.
93
GSE81538

Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative [cohort 405]

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
GEO Homo sapiens bulk RNA-seq 405 samples intent-aware-scoring-v19
GEO source Trusted counts

No warnings

94
GSE83794

Next-generation Sequencing (NGS) identified genome-wide profiles of piwi-interacting RNAs (piRNAs) in human Epithelial Ovarian Cancers (EOCa)

Not suitable Overall 34% Suitability 0% Metadata 100%
Case ovarian cancer Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 3 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Total sample count is below the minimum needed for two comparison groups.
95
GSE87517

Immune escape in breast cancer during in situ to invasive carcinoma transition

Not suitable Overall 34% Suitability 0% Metadata 100%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 41 samples intent-aware-scoring-v19
GEO source Trusted counts
info Ambiguous sample metadata was detected in 27 sample(s): GSM2332997 matched "not available"; GSM2332998 matched "not available"; GSM2332999 matched "not available"; additional ambiguous samples omitted. Review these samples before inclusion or manual group assignment.
96
GSE102101

Transcriptomics profiles of patient-matched normal kidney and ccRCC pairs

Not suitable Overall 34% Suitability 0% Metadata 85%
Case tumor sample Control normal tissue
Tumor vs matched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs matched normal · Tissue · suitability 0%.
  • Prioritized for patient tissue tumor-vs-normal triage.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 20 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Tissue or cell type could not be normalized.
97
GSE113113

Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile

Not suitable Overall 34% Suitability 0% Metadata 85%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Biopsy
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Biopsy · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 52 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized.
98
GSE113617

RNA biotype-associated molecular classification in hepatitis B-related hepatocellular carcinoma

Not suitable Overall 34% Suitability 0% Metadata 85%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: not a colorectal/GI cancer cohort.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 78 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized.
99
GSE117627

Intrahepatic MAIT cell gene expression revealed by RNA-seq

Not suitable Overall 34% Suitability 0% Metadata 85%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 15 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized.
100
GSE119336

RNA over-editing leads to aggressiveness of intrahepatic cholangiocarcinoma [RNA-Seq]

Not suitable Overall 34% Suitability 0% Metadata 85%
Case tumor sample Control normal tissue
Tumor vs unmatched normal Tissue
Intent rationale for Patient tissue tumor-vs-normal

Dataset does not meet the current suitability threshold.

  • Tumor vs unmatched normal · Tissue · suitability 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Downgraded disease context: colorectal/GI relevance is unclear.
  • Processed data is available for downstream review.
  • 1 warning require review.
GEO Homo sapiens bulk RNA-seq 30 samples intent-aware-scoring-v19
GEO source Trusted counts
warning Disease or condition label could not be normalized.